IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma

PURPOSE: Glioblastoma (GBM) is the most aggressive primary brain tumor in adults with a median survival of 15–20 months. Numerous approaches and novel therapeutics for treating GBM have been investigated in the setting of phase III clinical trials, including a recent analysis of the immune checkpoin...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Clin Cancer Res
Κύριοι συγγραφείς: Ladomersky, Erik, Zhai, Lijie, Lenzen, Alicia, Lauing, Kristen L., Qian, Jun, Scholtens, Denise M., Gritsina, Galina, Sun, Xuebing, Liu, Ye, Yu, Fenglong, Gong, Wenfeng, Liu, Yong, Jiang, Beibei, Tang, Tristin, Patel, Ricky, Platanias, Leonidas C., James, C. David, Stupp, Roger, Lukas, Rimas V., Binder, David C., Wainwright, Derek A.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2018
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5984675/
https://ncbi.nlm.nih.gov/pubmed/29500275
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-3573
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια